A Vaccine to Prevent Leishmaniasis
Abstract
Building on extensive preliminary data and an established consortium of academic, government, military, and product development partners, we propose to develop a production process for a novel, bivalent vaccine against leishmaniasis, a serious neglected tropical disease (NTD) of military and civilian personnel now spreading rapidly in conflict zones of the Middle East and Central Asia. The proposed Cutaneous Leishmania Vaccine (CL-Vax) is a bivalent, recombinant protein-based vaccine that will be comprised of a specific Leishmania parasite antigen together with a novel sand fly salivary antigen, co-administered at bedside with an adequate adjuvant. The components of the vaccine will be extensively characterized, and their immunogenicity and efficacy will be confirmed in animal models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1086269
Entities
People
- Peter J. Hotez
Organizations
- Baylor College of Medicine